Capstone Therapeutics (NASDAQ:CAPS – Get Free Report) and Willis Lease Finance (NASDAQ:WLFC – Get Free Report) are both small-cap industrials companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.
Earnings & Valuation
This table compares Capstone Therapeutics and Willis Lease Finance”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Capstone Therapeutics | $48.11 million | 0.03 | -$21.23 million | ($91.37) | -0.02 |
| Willis Lease Finance | $828.30 million | 1.26 | $113.76 million | $3.37 | 13.57 |
Willis Lease Finance has higher revenue and earnings than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than Willis Lease Finance, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations for Capstone Therapeutics and Willis Lease Finance, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Capstone Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Willis Lease Finance | 1 | 1 | 1 | 1 | 2.50 |
Willis Lease Finance has a consensus target price of $75.50, indicating a potential upside of 65.10%. Given Willis Lease Finance’s stronger consensus rating and higher probable upside, analysts clearly believe Willis Lease Finance is more favorable than Capstone Therapeutics.
Insider & Institutional Ownership
2.5% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 93.7% of Willis Lease Finance shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Comparatively, 56.4% of Willis Lease Finance shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Capstone Therapeutics has a beta of -1.35, indicating that its stock price is 235% less volatile than the S&P 500. Comparatively, Willis Lease Finance has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.
Profitability
This table compares Capstone Therapeutics and Willis Lease Finance’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Capstone Therapeutics | -31.00% | -167.41% | -38.24% |
| Willis Lease Finance | 9.38% | 11.89% | 2.20% |
Summary
Willis Lease Finance beats Capstone Therapeutics on 15 of the 15 factors compared between the two stocks.
About Capstone Therapeutics
Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury. The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.
About Willis Lease Finance
Willis Lease Finance Corporation is an aviation services company specializing in the leasing and servicing of commercial aircraft engines. Founded in 1985, the company provides engines and related equipment to airlines, aircraft operators and maintenance providers. Its activities include leasing aircraft engines and auxiliary power units, trading engines and parts, and providing aviation maintenance and repair services. Willis Lease Finance also manages engine and equipment portfolios for customers.
Receive News & Ratings for Capstone Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capstone Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
